A medical device company with global reach but an unfinished American chapter steps before one of healthcare's most scrutinized investor audiences. Establishment Labs, whose Motiva Implants are already trusted in more than 80 countries, brings its CEO and CFO to the Cowen 41st Annual Healthcare Conference in March 2021 — a moment that carries weight not merely as a financial ritual, but as a signal of where the company believes it stands in its longer journey toward the U.S. market.
Establishment Labs to Present at Cowen Healthcare Conference
Already in 80 countries, waiting for the U.S. to decide
Mark
Why does a medical device company present at a healthcare investor conference? What's the actual purpose?
Mimi
It's about access and credibility. Cowen's conference draws institutional investors, analysts, and fund managers who make decisions about where healthcare capital flows. For a company like Establishment Labs, still waiting on FDA approval in the U.S., these presentations are a chance to tell your story directly to the people deciding whether to buy or hold your stock.
Mark
So they're not announcing anything new—they're just showing up?
Mimi
Not necessarily. The timing matters. They're in the middle of a clinical trial. Investors will be listening for any signals about timeline, enrollment numbers, or commercial strategy. Even if no formal announcement comes, the tone and confidence in the room tells a story.
Mark
The implants are already in 80 countries. Why does the U.S. market matter so much?
Mimi
Scale and pricing power. The U.S. is the world's largest market for cosmetic and reconstructive surgery. Approval here means access to a much larger patient base and typically higher margins. It's the difference between being a global player and being a dominant one.
Mark
What happens if the FDA approval takes longer than expected?
Mimi
That's the risk investors are pricing in. Every quarter without approval is a quarter of cash burn without corresponding U.S. revenue. The conference is partly about managing those expectations and showing the company has a plan beyond just waiting.
Mark
Is there anything unusual about their manufacturing setup?
Mimi
Not unusual—actually the opposite. They're meeting the highest standards: ISO compliance, FDA regulations, MDSAP certification. That's table stakes for a company serious about U.S. approval. It signals they've built the infrastructure to scale if and when that approval comes.
O Pulso
- Establishment Labs is mid-stride in a U.S. FDA clinical trial that began in April 2018, and the outcome will determine whether its flagship product can enter the world's most consequential medical market.
- The company's leadership is stepping into one of healthcare investing's most visible forums, where institutional eyes will be measuring confidence as much as data.
- With Motiva Implants already distributed across 80+ countries and two rigorously certified manufacturing facilities, the company arrives at the conference with credibility — but the American approval remains the missing piece.
- A live webcast ensures the presentation reaches beyond the conference room, extending the company's message to shareholders and observers who will be listening for any signal on the FDA timeline.
A medical device company with global reach but an unfinished American chapter steps before one of healthcare's most scrutinized investor audiences. Establishment Labs, whose Motiva Implants are already trusted in more than 80 countries, brings its CEO and CFO to the Cowen 41st Annual Healthcare Conference in March 2021 — a moment that carries weight not merely as a financial ritual, but as a signal of where the company believes it stands in its longer journey toward the U.S. market.
Establishment Labs, the company behind Motiva Implants, is bringing its leadership to one of healthcare's most closely watched investor stages this spring. CEO and Founder Juan José Chacón-Quirós and CFO Renee Gaeta will present at the Cowen 41st Annual Healthcare Conference on the morning of March 2, 2021 — a moment that carries meaning beyond routine investor relations.
The company, listed on Nasdaq under ESTA, has built its identity around silicone gel-filled breast implants designed for both cosmetic and reconstructive use. Motiva Implants, the heart of its MotivaImagine platform, are already sold in more than 80 countries through a combination of exclusive distributors and the company's own sales force.
What gives this appearance particular weight is timing. Establishment Labs received FDA investigational device exemption in March 2018 and launched its U.S. clinical trial the following April. That trial remains ongoing — meaning the conference offers a natural moment to update investors on where the approval process stands and what the path to the American market looks like.
The company's manufacturing operations meet ISO13485:2016 and FDA 21 CFR 820 standards under the MDSAP program, and its portfolio extends beyond implants to include the Divina 3D Simulation System for pre-surgical visualization. For those who cannot attend in person, the presentation will be streamed live and archived on the company's investor relations website.
Establishment Labs, the medical device company behind Motiva Implants, is taking its story to one of healthcare's most closely watched investor conferences this March. CEO and Founder Juan José Chacón-Quirós and Chief Financial Officer Renee Gaeta will present to the assembled audience at the Cowen 41st Annual Healthcare Conference on the morning of March 2, 2021, starting at 9:50 am Eastern time.
The company, which trades on the Nasdaq under the ticker ESTA, has built itself around a focused mission: designing and manufacturing silicone gel-filled breast implants for both cosmetic and reconstructive purposes. Motiva Implants, the flagship product, represents the centerpiece of what the company calls the MotivaImagine platform. The implants are already available in more than 80 countries through a network of exclusive distributors and the company's own sales team.
What makes this conference appearance potentially significant is the timing relative to the company's regulatory journey in the United States. Establishment Labs received an investigational device exemption from the FDA in March 2018 and launched its clinical trial for Motiva Implants in the American market the following April. That trial is still ongoing, which means the company is in the middle of the approval process that will determine whether these implants can be sold domestically. The presentation offers an opportunity for the company to update investors on where that process stands.
The company operates two manufacturing facilities that meet the stringent standards required for medical devices: both are ISO13485:2016 compliant and operate under FDA 21 CFR 820 regulations as part of the MDSAP program. Beyond the implants themselves, Establishment Labs has developed complementary offerings, including the Divina 3D Simulation System, which allows surgeons and patients to visualize potential outcomes before surgery.
For those unable to attend the conference in person, Establishment Labs will stream the presentation live through its investor relations website. The webcast will remain available for viewing after the event concludes, ensuring that shareholders and interested parties who cannot tune in during the live broadcast can catch up on what the company's leadership has to say about its strategy and prospects.
Citações Notáveis
Establishment Labs is focused on women's health, initially in the breast aesthetics and reconstruction market— Company description
Quer a matéria completa?
Leia o original em Markets Insider ↗
Economy & Finance